EFFECTS OF BIOLOGIC THERAPIES ON SYMPTOMS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A NARRATIVE REVIEW
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.5898Keywords:
Rheumatoid Arthritis, Biologic Therapy, TNF Inhibitors, Interleukin-6 Inhibitors, Treatment Efficacy, Disease Activity (DAS28)Abstract
Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease causing progressive joint destruction, pain, disability, and reduced quality of life. Many patients respond inadequately to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), necessitating more effective treatment strategies.
Background: Biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic therapies have transformed RA management by targeting inflammatory pathways such as tumor necrosis factor (TNF), interleukin-6 (IL-6), and Janus kinase (JAK) signaling.
Methods: A narrative-systematic review of randomized clinical trials and observational studies was conducted to evaluate the efficacy and safety of biologic therapies in RA patients with inadequate response to csDMARDs. Outcomes included ACR20/50/70 response rates, Disease Activity Score in 28 joints (DAS28), remission rates, functional outcomes, and adverse events.
Results: Biologic therapies significantly reduced disease activity and improved patient outcomes. TNF inhibitors combined with methotrexate achieved the most consistent efficacy, with ACR20, ACR50, and ACR70 responses reaching 78%, 57%, and 31%, respectively. Remission rates approached 40–50% in several studies. IL-6 inhibitors and JAK inhibitors provided rapid pain relief and functional improvement. Overall, remission or low disease activity was achieved in 30–60% of patients. Although biologic therapies increased the risk of adverse events, particularly infections, their safety profile remained acceptable with proper monitoring.
Discussion: The findings demonstrate that biologic and targeted therapies represent a major advancement in RA treatment, particularly in patients resistant to conventional therapies. Differences in efficacy and safety profiles support individualized treatment selection, while methotrexate combination therapy may further enhance clinical response.
Conclusion: Biologic therapies substantially improve disease control, physical function, and quality of life in RA patients. TNF inhibitors, IL-6 inhibitors, and JAK inhibitors remain central to modern RA management, although continued long-term safety monitoring and personalized therapeutic strategies are essential.
References
Weinblatt, M. E., Keystone, E. C., Furst, D. E., et al. (2006). Long-term efficacy and safety of adalimumab plus methotrexate in rheumatoid arthritis: ARMADA 4-year study. Annals of the Rheumatic Diseases, 65, 753–759.
Strand, V., Ginsberg, S., Pedersen, R., et al. (2017). Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in rheumatoid arthritis. Annals of the Rheumatic Diseases, 76, 840–849.
Bitoun, S., Hässler, S., Ternant, D., et al. (2023). Response to biologic drugs in patients with rheumatoid arthritis and antidrug antibodies. JAMA Network Open, 6, e233098.
Aaltonen, K. J., Virkki, L. M., Malmivaara, A., et al. (2012). Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in RA. PLoS ONE, 7, e30275.
Schiff, M., Keiserman, M., Codding, C., et al. (2006). Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: A phase III study. Arthritis & Rheumatism, 54, 718–728.
Leng, X., Leszczyński, P., Jeka, S., Liu, S., Liu, H., Miakisz, M., et al. (2024). A phase 3 randomized double-blind study comparing BAT1806/BIIB800 with tocilizumab in rheumatoid arthritis. Arthritis Research & Therapy, 26, 157.
Jones, G., Sebba, A., Gu, J., Lowenstein, M. B., Calvo, A., Gomez-Reino, J. J., et al. (2010). Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: The AMBITION study. Annals of the Rheumatic Diseases, 69, 88–96.
Best, J. H., Vlad, S. C., & Pei, J. (2015). Comparative cost per response for 4 clinical endpoints with tocilizumab monotherapy vs adalimumab monotherapy in a head-to-head randomized double-blind superiority trial (ADACTA) in patients with rheumatoid arthritis. Journal of Medical Economics, 18(9), 755–762. https://doi.org/10.3111/13696998.2015.1044271
Bergman, M., Tundia, N., Martin, N., Suboticki, J. L., Patel, J., Goldschmidt, D., et al. (2022). Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial. Arthritis Research & Therapy, 24, 155.
Li, T., Wells, G., Westhovens, R., Emery, P., Becker, J. C., & Tugwell, P. (2011). Improvements in participation in usual daily activities in patients with rheumatoid arthritis treated with abatacept. Value in Health, 14(3), 361–370.
Almeida, C., Choy, E. H. S., Hewlett, S., Kirwan, J. R., Cramp, F., Chalder, T., et al. (2016). Biologic interventions for fatigue in rheumatoid arthritis. Cochrane Database of Systematic Reviews, (6), CD008334.
Smolen, J. S., van Vollenhoven, R. F., Kavanaugh, A., Strand, V., Vencovsky, J., Schiff, M., et al. (2015). Certolizumab pegol plus methotrexate: 5-year results from the RAPID 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 74(10), 1777–1784. https://doi.org/10.1136/annrheumdis-2014-205334
Taylor, P. C., Lee, Y. C., Fleischmann, R., et al. (2019). Achieving pain control in rheumatoid arthritis with baricitinib or adalimumab plus methotrexate: Results from the RA-BEAM trial. Journal of Clinical Medicine, 8(6), 831.
Keystone, E. C., Taylor, P. C., Tanaka, Y., Gaich, C., DeLozier, A. M., Dudek, A., et al. (2017). Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: Secondary analyses from the RA-BEAM study. Annals of the Rheumatic Diseases, 76(11), 1853–1861. https://doi.org/10.1136/annrheumdis-2017-211259
Keystone, E., Landewé, R., van Vollenhoven, R., Combe, B., Strand, V., Mease, P., et al. (2014). Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. Annals of the Rheumatic Diseases, 73(12), 2094–2100. https://doi.org/10.1136/annrheumdis-2013-203695
Keystone, E. C., Genovese, M. C., Hall, S., Bae, S. C., Han, C., Gathany, T. A., et al. (2016). Safety and efficacy of subcutaneous golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: Final 5-year results of the GO-FORWARD trial. The Journal of Rheumatology, 43(2), 298–306. https://doi.org/10.3899/jrheum.150460
Singh, J. A., Christensen, R., Wells, G. A., Suarez-Almazor, M. E., Buchbinder, R., Lopez-Olivo, M. A., et al. (2009). Biologics for rheumatoid arthritis: An overview of Cochrane reviews. Cochrane Database of Systematic Reviews, (4), CD007848. https://doi.org/10.1002/14651858.CD007848
Agarwal, S. K. (2011). Biologic agents in rheumatoid arthritis: An update for managed care professionals. Journal of Managed Care Pharmacy, 17(9 Suppl B), S14–S18. https://doi.org/10.18553/jmcp.2011.17.s9-b.s14
Adas, M. A., Allen, V. B., Yates, M., et al. (2021). A systematic review and network meta-analysis of the safety of early interventional treatments in rheumatoid arthritis. Rheumatology, 60, 4450–4462.
Findeisen, K. E., Sewell, J., & Ostor, A. J. K. (2021). Biological therapies for rheumatoid arthritis: An overview for the clinician. Biologics, 15, 343–352.
Malinowska-Lipień, I., Cepielik, A., Kliś-Kalinowska, A., Poręba, D., Lompart, Ł., Kalemba, U., & Lickiewicz, J. (2025). The impact of biological treatment on the clinical response and functioning of patients with rheumatoid arthritis. Family Medicine & Primary Care Review, 27(1), 57–62.
Strand, V., Mease, P., Burmester, G. R., Nikai, E., Coteur, G., van Vollenhoven, R. F., et al. (2009). Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: Results from the RAPID 1 randomized controlled trial. Arthritis Research & Therapy, 11(6), R170. https://doi.org/10.1186/ar2859
Keystone, E. C., Genovese, M. C., Klareskog, L., Hsia, E. C., Hall, S. T., Miranda, P. C., et al. (2009). Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: The GO-FORWARD study. Annals of the Rheumatic Diseases, 68(6), 789–796. https://doi.org/10.1136/ard.2008.099010
Breedveld, F. C., Weisman, M. H., Kavanaugh, A. F., Cohen, S. B., Pavelka, K., van Vollenhoven, R. F., et al. (2006). A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis & Rheumatism, 54(1), 26–37. https://doi.org/10.1002/art.21519
Emery, P., Breedveld, F. C., van der Heijde, D., Ferraccioli, G., Dougados, M., Robertson, D., et al. (2010). Two-year clinical and radiographic results with combination etanercept–methotrexate therapy versus monotherapy in early rheumatoid arthritis: A two-year, double-blind, randomized study. Arthritis & Rheumatism, 62(3), 674–682. https://doi.org/10.1002/art.27236
Smolen, J. S., Kay, J., Doyle, M., Landewé, R., Matteson, E. L., Gaylis, N., et al. (2015). Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor alpha inhibitors: Findings with up to five years of treatment in the GO-AFTER study. Annals of the Rheumatic Diseases, 74(12), 2109–2116. https://doi.org/10.1136/annrheumdis-2014-206959
Schiff, M., Weinblatt, M. E., Valente, R., van der Heijde, D., Citera, G., Elegbe, A., et al. (2014). Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Two-year efficacy and safety findings from the AMPLE trial. Annals of the Rheumatic Diseases, 73(1), 86–94. https://doi.org/10.1136/annrheumdis-2013-203843
Emery, P., Burmester, G. R., Bykerk, V. P., Combe, B., Furst, D. E., Barre, E., et al. (2015). Evaluating drug-free remission with abatacept in early rheumatoid arthritis: Results from the phase 3b AVERT study. Annals of the Rheumatic Diseases, 74(1), 19–26. https://doi.org/10.1136/annrheumdis-2014-206106
Toyoshima, J., Kaibara, A., Shibata, M., Kaneko, Y., Izutsu, H., & Nishimura, T. (2020). Exposure–response modeling of peficitinib efficacy in patients with rheumatoid arthritis. Clinical Pharmacology in Drug Development, 9(4), 489–499. https://doi.org/10.1002/cpdd.739
Toyoshima, J., Kaibara, A., Shibata, M., Kaneko, Y., Izutsu, H., & Nishimura, T. (2021). Exposure–response modeling of peficitinib efficacy in patients with rheumatoid arthritis. Pharmacology Research & Perspectives, 9, e00744.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Emilia Przybyszewska, Piotr Przybyszewski, Agnieszka Filarecka, Weronika Winiarska, Wiktoria Bełcikowska-Skowron, Aleksandra Siegmund, Marzena Chrapczyńska, Julia Gatniewska, Martyna Sienicka, Paulina Prudzic
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
